Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493).

Sparano JA, Weller E, Nazeer T, Habermann T, Traynor AE, Manalo J, Cassileth P. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002 Sep 01; 100(5):1634-40.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.